Preimplantation Genetic Testing Industry

The global preimplantation genetic testing market size was estimated at USD 802.2 million in 2023 and is expected to grow at a CAGR of 10.3% from 2024 to 2030.

The growing prevalence of single gene, mitochondrial, and other genetic disorders is expected to drive the demand for preimplantation diagnosis and screening processes in the coming years. The Florida Department of Health reports that approximately one in every 33 babies in the U.S. is born with a congenital disability, impacting nearly 120,000 babies each year. With new tests being launched, the demand is expected to grow in coming years. For instance, in July 2023, Thermo Fisher Scientific Inc. launched 2 tests based on NGS for preimplantation genetic testing-aneuploidy (PGT-A).

Preimplantation genetic diagnosis (PGD) is utilized prior to the IVF process to ensure a successful pregnancy. PGD is employed in IVF cycles for women who have experienced multiple miscarriages or previous pregnancies with chromosomal abnormalities. It is particularly beneficial for couples at risk of hereditary disorders, thereby positively impacting market growth.

Gather more insights about the market drivers, restrains and growth of the Global Preimplantation Genetic Testing market

Preimplantation Genetic Testing Market Segments:

Drivers, Opportunities & Restraints

The rising incidence of genetic diseases has fueled the demand for preimplantation genetic testing (PGT). With increasing prevalence of genetic disorders, PGT has become crucial in IVF procedures. This testing helps identify and prevent the transfer of genetic abnormalities, enhancing the likelihood of successful pregnancies. Innovations such as PGT-A and monogenic diseases (PGT-M) have further improved outcomes, reducing miscarriage rates and the risk of hereditary conditions. Consequently, the adoption of PGT is expected to grow, driven by its benefits in detecting and managing disorders effectively.

Industry Dynamics

The preimplantation genetic testing market has seen significant innovation, including advancements such as PGT-A and PGT-M. These innovations improve accuracy, reduce risks, and enhance pregnancy success rates, driving market growth and offering better outcomes for individuals facing genetic and fertility challenges.

Procedure Insights & Trends

The preimplantation genetic diagnosis segment dominated the preimplantation genetic testing market and contributed 77.0% of the market share in 2023. Growing awareness among healthcare professionals and consumers about genetic testing for specific gene mutations is a key driver of the segment's growth. The increasing incidence of single gene diseases and translocation cases, coupled with the effective implementation of NGS technology for genetic testing by market players, further propels this growth. PGD services enable the examination of embryos to identify specific gene mutations, helping to reduce the incidence of these diseases in newborns.

Product Insights & Trends

“Reagents and consumables segment is expected to witness growth at 10.9% CAGR”

The reagents and consumables segment dominated the preimplantation genetic testing market and contributed 49.1% of the market share in 2023. The rising adoption of PGT in the IVF process is boosting the demand for reagents and consumables. Annually, more than 3.0 million IVF cycles are performed worldwide, resulting in over 700,000 deliveries using IVF. In addition, the growing use of advanced testing technologies such as next-generation sequencing, polymerase chain reaction, and fluorescent in-situ hybridization is expected to drive segment growth.

Technology Insights & Trends

“Next-generation sequencing (NGS) is exponentially growing at a CAGR of 11.0%”

The Polymerase Chain Reaction (PCR) segment dominated the preimplantation genetic testing market and contributed 39.8% to the market share in 2023. High market penetration, cost-effectiveness, and the high accuracy of PCR tests are key factors supporting the segment's significant market share. PCR increases the likelihood of producing a large number of copies of a specific genome segment, enhancing the detection of chromosomal abnormalities. This technology is both specific and sensitive, making it suitable for various types of genetic diagnoses.

Application Insights & Trends

“Aneuploidy screening to register fastest growth of 11.4%”

The aneuploidy screening segment dominated the preimplantation genetic testing market and contributed 26.4% of market share in 2023. Aneuploidy screening plays a crucial role in assessing embryo quality during IVF procedures. The growing adoption of aneuploidy screening and the introduction of new products are expected to propel segment growth.

End Use Insights & Trends

“Fertility centers are technologically well-equipped and is expected to grow at 11.0%”

In 2023, the hospital segment captured the largest revenue share, accounting for approximately 38.9%. Factors driving this growth include high patient volume, enhanced healthcare infrastructure, and the availability of IVF services in both public and private hospitals. Couples seeking fertility treatments often choose hospitals due to their advanced technological capabilities.

Regional Insights

North America preimplantation genetic testing market due to rising prevalence of various disorders such as increasing number of labs offering PGT, rising awareness, high incidence of hereditary disorders and other diseases such as PCOS, chlamydia.

Browse through Grand View Research's  Clinical Diagnostics Industry Research Reports.

• The global In vitro fertilization market size was valued at USD 25.3 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 5.54% from 2024 to 2030.
• The global ovarian cancer diagnostics market was valued at USD 4.60 billion in 2023 and is expected to grow at a CAGR of 5.0% during the forecast period.

Key Preimplantation Genetic Testing Company Insights

Some of the key players operating in the market include Quest Diagnostics Incorporated; Natera, Inc.; Illumina. Inc.

• llumina, Inc. primarily operates within the life sciences and biotechnology vertical. The company specializes in sequencing and genomics, providing advanced tools and technologies that enable researchers & professionals to analyze and decode DNA with exceptional accuracy & efficiency. Illumina’s innovations have broad applications in various industries, including healthcare, agriculture, and scientific research. It is a leading player in genomics and driving advancements in personalized medicine, genetic discovery, and more.
• Quest Diagnostics Incorporated is a publicly owned medical diagnostics company that provides clinical testing services, such as gene-based & esoteric testing, routine testing, and drugs-of-abuse testing. Its service portfolio includes anatomic pathology services & related services to healthcare providers, risk assessment services for life insurers, and others, as well as central laboratory testing for clinical trials. It has geographical presence in Mexico, India, Ireland, and the UK. Several international diagnostic laboratories, hospitals, and clinics are partners to the company.

GenEmbryomics, Color Health, Inc., and EasyDNA are some of the emerging companies in the PGT market.

• Color Health, Inc. operates in healthcare technology and genomics verticals. The company delivers healthcare solutions that focus on genetics and genomics. Color Health also offers genetic testing and counseling services, leveraging the power of genetic information to provide insights into individuals’ health risks, including hereditary conditions and cancer predispositions.
• EasyDNA primarily operates in genetic testing and diagnostics. The company offers various DNA testing services to individuals and organizations. Its services cover diverse areas, including paternity testing, ancestry & genealogy analysis, health & wellness insights, and forensic DNA testing. EasyDNA provides accessible and user-friendly testing solutions, enabling individuals to gain access to their genetic heritage, family relationships, and potential health-related factors

Key Preimplantation Genetic Testing Companies:

The following are the leading companies in the preimplantation genetic testing market. These companies collectively hold the largest market share and dictate industry trends.

• Quest Diagnostics Incorporated
• Natera, Inc.
• COOPER SURGICAL, INC.
• Genea Pty Limited.
• Invitae Corporation
• Laboratory Corporation of America Holdings
• Thermo Fisher Scientific Inc.
• Bioarray S.L.
• Illumina, Inc.
• Igenomix
• RGI
• Hoffmann-La Roche Ltd

Order a free sample PDF of the Preimplantation Genetic Testing Market Intelligence Study, published by Grand View Research.